A phase II trial (ago 2.11) in platinum-resistant ovarian cancer: A randomized multicenter trial with sunitinib (su11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
K. H. Baumann, A. Du Bois, W. Meier, J. Rau, P. Wimberger, J. Sehouli, C. Kurzeder, F. Hilpert, A. Hasenburg, U. Canzler, L. C. Hanker, P. Hillemanns, B. Richter, K. Wollschlaeger, T. Dewitz, D. Bauerschlag, U. Wagner
Dive into the research topics of 'A phase II trial (ago 2.11) in platinum-resistant ovarian cancer: A randomized multicenter trial with sunitinib (su11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy'. Together they form a unique fingerprint.